Radar · Life Sciences in Seoul
Best Life Sciences Companies in Seoul, South Korea
The 405 best Life Sciences companies in Seoul, South Korea in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Cellid.
By Rohit KhannaTrends & Stories
405companies tracked
$3.5Bdisclosed funding
0unicorns
93have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × SEOUL
Our analysis of 50 Life Sciences companies
$4.0b in tracked funding; 40% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
40%cloud-native stacks
2025funding peak (by rounds)
2018median founding year
33median Fliar Index™
Ranked: Best Life Sciences companies in Seoul
| # | Company | Disclosed funding | Last round | Stage | Employees | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Cellid Developer of personalized vaccines to treat cancer and infectious diseases 32Patents top 32%Funding top 35%Innovation top 40%Moat top 45% All 8 signals ▾Patentstop 32% Fundingtop 35% Innovationtop 40% Moattop 45% Marketbottom 48% Globalbottom 35% Fin. healthbottom 35% Techbottom 22% Patents: 32 patents matched (strict assignee match) · 26 filings since 2022 vs 4 in 2017-21 Funding: Raised $2.4B across 1 rounds · 1 rounds over 12 yrs (0.1/yr) rank vs industry peers · Fliar Intelligence Index 32/100 | $2.4B | 120 mo ago | Public | 68 | 2014 | PHPNginxNaver Analytics+5 | 32 patents Patents concentrated in chemistry & materials | — |
| 2 | Standigm AI-based platform for drug discovery and development 48Patents top 19%Moat top 19%Innovation top 21%Talent top 28% All 10 signals ▾Patentstop 19% Moattop 19% Innovationtop 21% Talenttop 28% AItop 30% Fundingtop 36% Globalbottom 42% Newsbottom 27% Techbottom 21% Marketbottom 18% Patents: 101 patents matched (strict assignee match) · 77 filings since 2022 vs 24 in 2017-21 Moat: Editorial + unicorn rating 8/10 · IP moat: 101 patents rank vs industry peers · Fliar Intelligence Index 48/100 | $70M | 59 mo ago | Series C | 3 | 2015 | — | 101 patents Patents concentrated in health & consumer products | — |
| 3 | Illimis Therapeutics Developer of antibody-based drugs to treat neurological conditions 35Funding top 28%Moat top 31%Patents top 38%Innovation top 45% All 8 signals ▾Fundingtop 28% Moattop 31% Patentstop 38% Innovationtop 45% Talentbottom 49% Globalbottom 40% Marketbottom 39% Techbottom 30% Funding: Raised $57.4M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 24 patents rank vs industry peers · Fliar Intelligence Index 35/100 | $57M | 11 mo ago | Series B | 26 | 2021 | PHPApache HTTP ServerCloudflare+11 | 24 patents Therapeutic biologics targeting TAM receptors and ErbB4 for immune and neurodegenerative diseases | — |
| 4 | ExocoBio Developer of exosome-based therapeutics for regenerative medicine | $47M | 69 mo ago | Series C | 99 | 2017 | PHPNginx | 203 patents Exosome-derived bioactive ingredients for anti‑inflammatory, wound‑healing and cosmetic applications | — |
| 5 | Galaxy Provider of a drug discovery platform that integrates AI, physics, and chemistry to design various… 37Funding top 28%News top 36%Talent bottom 49%Market bottom 44% All 5 signals ▾Fundingtop 28% Newstop 36% Talentbottom 49% Marketbottom 44% Globalbottom 33% Funding: Raised $47.0M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) News: 3 BI events in 12 mo (of 3 tracked, 1 types) · Top themes: Funding rank vs industry peers · Fliar Intelligence Index 37/100 | $47M | 4 mo ago | Series B | 23 | 2020 | — | — | — |
| 6 | Wellmarker Bio Developer of biomarker-based therapeutics for the treatment of cancer | $45M | 83 mo ago | Series B | 58 | 2016 | — | 85 patents Targeted antibody therapeutics and biomarkers for cancer and kinase inhibitor response | — |
| 7 | Aston Sci. Developer of therapeutic solutions for the treatment of cancer, CNS diseases, and geriatric diseases | $40M | 54 mo ago | Series C | 24 | 2018 | — | — | — |
| 8 | Onconic Therapeutics Developer of therapeutics for the treatment of cancer and gastrointestinal diseases 24Patents top 22%Innovation top 25%Moat top 29%Funding top 36% All 10 signals ▾Patentstop 22% Innovationtop 25% Moattop 29% Fundingtop 36% Talentbottom 49% Globalbottom 42% Newsbottom 37% Growthbottom 30% Marketbottom 23% Techbottom 17% Patents: 114 patents matched (strict assignee match) · 107 filings since 2022 vs 7 in 2017-21 Innovation: 114 patents (top 24% of patent-holders) · 107 filings since 2022 vs 7 in 2017-21 rank vs industry peers · Fliar Intelligence Index 24/100 | $35M | 42 mo ago | Public | 6 | 2020 | JavaPHPCentOS+8 | 114 patents Solid-form and salt optimization of heterocyclic anticancer small‑molecule therapeutics | — |
| 9 | ROKIT Healthcare Provider of 4D bio-printer solutions for tissue regenerative 64Patents top 24%Innovation top 26%Tech top 28%Product top 28% All 11 signals ▾Patentstop 24% Innovationtop 26% Techtop 28% Producttop 28% Moattop 29% Fundingtop 33% Growthtop 35% Markettop 50% Talentbottom 49% Fin. healthbottom 43% Globalbottom 42% Patents: 168 patents matched (strict assignee match) · 84 filings since 2022 vs 84 in 2017-21 Innovation: 168 patents (top 10% of patent-holders) · 84 filings since 2022 vs 84 in 2017-21 rank vs industry peers · Fliar Intelligence Index 64/100 | $30M | 3 mo ago | Public | 65 | 2012 | Cart FunctionalityWordPressMySQL+25 | 168 patents Personalized 3D bioprinting of regenerative dermal and cartilage scaffolds for diabetic foot care | 2 partnerships |
| 10 | Curiox Developer of wall-less plates and washers for automated cell-based assays | $30M | 51 mo ago | Public | 57 | 2007 | WordPressBetterDocsMySQL+41 | — | 1 launch · 1 award |
| 11 | Kanaph Developer of immunocytokine platform for treating cancer | $30M | 68 mo ago | Public | 13 | 2019 | PHPGSAPApache HTTP Server+8 | 2 patents Chain retention mechanisms for foldable bicycles preventing chain separation. | — |
| 12 | Mepsgen Developer of human organ model chips for pharmaceutical development 42Patents top 24%Moat top 32%Funding top 34%Innovation top 35% All 9 signals ▾Patentstop 24% Moattop 32% Fundingtop 34% Innovationtop 35% Growthtop 35% Talentbottom 49% Globalbottom 43% Marketbottom 33% Techbottom 24% Patents: 49 patents matched (strict assignee match) · 47 filings since 2022 vs 2 in 2017-21 Moat: Editorial + unicorn rating 4/10 · IP moat: 49 patents rank vs industry peers · Fliar Intelligence Index 42/100 | $29M | 18 mo ago | Series C | 20 | 2019 | DreamWeaverPHPYouTube+10 | 49 patents Microfluidic fabrication of lipid‑based nanoparticles and HDL mimetics for drug delivery | — |
| 13 | Lemonex Developer of drug delivery technology and biosensor technology | $27M | 61 mo ago | Series C | 9 | 2013 | — | 181 patents Nanocarrier-based drug and nucleic‑acid delivery systems for antiviral and cancer therapies | — |
| 14 | NEXEL Provider of induced pluripotent stem cell (iPSC)-derived cells and organoids | $27M | 62 mo ago | Series B | 22 | 2012 | PHPBootstrapNginx+10 | 68 patents Patents concentrated in health & consumer products | — |
| 15 | LISCure Developer of bacteria-mediated immunotherapeutic drugs for multiple diseases | $26M | 63 mo ago | Series B | 7 | 2018 | — | — | — |
| 16 | 3billion Provider of AI-driven clinical diagnostic testing platform for rare genetics disease 74Product top 19%Tech top 22%AI top 25%Patents top 26% All 12 signals ▾Producttop 19% Techtop 22% AItop 25% Patentstop 26% Talenttop 28% Innovationtop 32% Moattop 32% Fundingtop 34% Growthtop 35% Marketbottom 49% Globalbottom 43% Fin. healthbottom 36% Product: 3 distinct product lines · Company stage: Public Tech: 49 technologies across 5/8 capability areas · Cloud: Amazon Cloudfront, Amazon S3 rank vs industry peers · Fliar Intelligence Index 74/100 | $26M | 1 mo ago | Public | 75 | 2016 | TurbopackSentryApple iCloud Mail+21 | 59 patents AI-powered genomic variant analysis and clinical symptom similarity for precision medicine | 1 partnership |
| 17 | Tikaros Developer of immunotherapies for the treatment of cancer | $24M | 57 mo ago | Series C | — | 2018 | Windows ServerYouTubeMicrosoft ASP.NET+12 | — | — |
| 18 | Must Bio Developer of immunotherapeutics for cancer treatment 27Funding top 29%Talent bottom 49%Market bottom 36%Global bottom 29% All 4 signals ▾Fundingtop 29% Talentbottom 49% Marketbottom 36% Globalbottom 29% Funding: Raised $23.5M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 27/100 | $24M | 3 mo ago | Series C | 18 | 2021 | — | — | — |
| 19 | Shaperon Developer of therapies for multiple diseases 24Patents top 20%Innovation top 24%Funding top 29%Moat top 35% All 10 signals ▾Patentstop 20% Innovationtop 24% Fundingtop 29% Moattop 35% Newstop 39% Talentbottom 49% Globalbottom 40% Marketbottom 30% Fin. healthbottom 18% Techbottom 16% Patents: 116 patents matched (strict assignee match) · 105 filings since 2022 vs 9 in 2017-21 Innovation: 116 patents (top 24% of patent-holders) · 105 filings since 2022 vs 9 in 2017-21 rank vs industry peers · Fliar Intelligence Index 24/100 | $23M | 2 mo ago | Public | 48 | 2008 | PHPUNIXOpenSSL+7 | 116 patents Therapeutic formulations of taurodeoxycholic acid and bispecific antibodies for inflammatory and respiratory diseases | — |
| 20 | Progen Developer of immunotherapies for immune diseases and cancer 62Growth top 5%Partners top 18%News top 19%Moat top 25% All 10 signals ▾Growthtop 5% Partnerstop 18% Newstop 19% Moattop 25% Patentstop 39% Innovationtop 48% Fundingbottom 49% Talentbottom 49% Marketbottom 48% Globalbottom 36% Partners: 5 contract events in 12 mo · Named contractor/client in 5 deals rank vs industry peers · Fliar Intelligence Index 62/100 | $23M | 38 mo ago | Series B | — | 2000 | — | 73 patents Engineered Fc-fusion and bispecific therapeutic proteins, including IL-10 variants, for biologics. | — |
| 21 | Haim Bio Developer of anticancer drug that block metabolic pathways | $20M | 55 mo ago | Series B | — | 2011 | — | — | — |
| 22 | NeuracleGenetics Developing gene therapies using adeno associated virus technology to treat various diseases 42Funding top 33%Market top 50%Talent bottom 49%Global bottom 36% All 4 signals ▾Fundingtop 33% Markettop 50% Talentbottom 49% Globalbottom 36% Funding: Raised $18.8M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Market: 30 employees (top 50% of Life Sciences) rank vs industry peers · Fliar Intelligence Index 42/100 | $19M | 9 mo ago | Series C | 30 | 2018 | — | — | — |
| 23 | Eutilex Developing T cell-based therapeutics and antibodies for the treatment of cancer. | $18M | 114 mo ago | Public | 103 | 2015 | PHPGSAPApache HTTP Server+6 | 191 patents Immuno‑oncology therapeutics: checkpoint antibodies, bispecifics, CAR‑T, and immune adjuvants | — |
| 24 | Uvic Steratics Developer of anti-cancer drugs based on Proteolysis Targeting Chimera 27Funding top 39%Talent bottom 49%Market bottom 39%Tech bottom 37% All 5 signals ▾Fundingtop 39% Talentbottom 49% Marketbottom 39% Techbottom 37% Globalbottom 37% Funding: Raised $17.6M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 27/100 | $18M | 17 mo ago | Series B | 41 | 2018 | Node.jsUbuntuReact+7 | — | — |
| 25 | Daan Biotherapeutics Developer of therapeutics for cancer treatment 19Moat top 38%Talent top 38%Patents top 43%Funding top 44% All 9 signals ▾Moattop 38% Talenttop 38% Patentstop 43% Fundingtop 44% Innovationbottom 47% Globalbottom 40% Growthbottom 35% Techbottom 31% Marketbottom 19% Moat: Editorial + unicorn rating 4/10 · IP moat: 8 patents Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 19/100 | $17M | 28 mo ago | Series A | 4 | 2020 | GnuboardMySQLPHP+18 | 8 patents Targeted cancer immunotherapy: anti-CEACAM5 antibodies and engineered T‑cell receptor therapies. | — |
| 26 | Deargen Developer of AI-based drug discovery platform for rare and intractable diseases | $17M | 51 mo ago | Series B | 39 | 2016 | — | 72 patents AI-driven small‑molecule design and target interaction prediction for drug discovery | — |
| 27 | MitoImmune Therapeutics Provides drug development for treating mitochondrial dysfunction 32Patents top 28%Moat top 32%Innovation top 34%Funding top 49% All 8 signals ▾Patentstop 28% Moattop 32% Innovationtop 34% Fundingtop 49% Talentbottom 49% Globalbottom 40% Techbottom 38% Marketbottom 28% Patents: 56 patents matched (strict assignee match) · 53 filings since 2022 vs 3 in 2017-21 Moat: Editorial + unicorn rating 5/10 · IP moat: 56 patents rank vs industry peers · Fliar Intelligence Index 32/100 | $14M | 32 mo ago | Series B | 16 | 2018 | WordPressMySQLPHP+26 | 56 patents Novel heterocyclic small‑molecule drugs (indole/dihydroacridine) for anti‑aging and renal therapies | — |
| 28 | Microbiotics Developer of small molecule therapeutics for infectious diseases 32Funding top 39%Talent bottom 49%Market bottom 44%Global bottom 29% All 4 signals ▾Fundingtop 39% Talentbottom 49% Marketbottom 44% Globalbottom 29% Funding: Raised $14.3M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 32/100 | $14M | 9 mo ago | Series B | 29 | 2016 | — | — | — |
| 29 | Oncocross Provider of AI-based drug discovery platform | $14M | 69 mo ago | Public | 10 | 2015 | PHPCodeIgniterBootstrap+14 | 132 patents AI-driven drug discovery and predictive therapeutics for cancer, kidney, and muscle diseases | 1 partnership |
| 30 | Geninus Developer of genomic-based disease prevention platform | $13M | 70 mo ago | Public | 94 | 2018 | — | 39 patents Molecular diagnostics and immuno‑oncology biomarkers for cancer detection and therapy prediction | — |
| 31 | Neogen TC Developer of cell therapies for the treatment of cancer | $13M | 62 mo ago | Series A | — | 2020 | — | — | — |
| 32 | Boostimmune Developer of therapeutics for cancer treatment | $13M | 47 mo ago | Series A | 5 | 2021 | — | 10 patents TCTP-based cancer biomarkers and therapeutic agents for immune‑modulating oncology. | — |
| 33 | NGeneBio In vitro cancer diagnostic products | $13M | 90 mo ago | Public | 124 | 2015 | Microsoft ASP.NETGSAPCloudflare+8 | 46 patents Genetic diagnostics and personalized therapeutics via nucleic‑acid amplification and microbiome analysis | — |
| 34 | Genacast Provider of liquid-biopsy-based cancer detection platform | $12M | 72 mo ago | Series B | 27 | 2016 | — | — | — |
| 35 | Abion Therapeutics for cancer and auto-immune diseases. | $11M | 130 mo ago | Public | 33 | 2007 | WordPressMySQLPHP+16 | 229 patents Kinase inhibitor small molecules and interferon‑beta biologics for cancer and antiviral therapies | — |
| 36 | CONNECTEVE Provider of AI-based automated robotic system for orthopedic disorders in the elderly 27Moat top 38%Innovation top 41%Funding top 41%Patents top 41% All 7 signals ▾Moattop 38% Innovationtop 41% Fundingtop 41% Patentstop 41% AItop 45% Globalbottom 36% Marketbottom 16% Moat: Editorial + unicorn rating 4/10 · IP moat: 20 patents Innovation: 20 patents (top 73% of patent-holders) · 20 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 27/100 | $10M | 15 mo ago | Series A | 1 | 2021 | — | 20 patents Robotic surgical systems and AI-driven orthopedic diagnostic tools for joint procedures | 1 award |
| 37 | Olive Healthcare Provider of device for wellness and medical purpose | $10M | 77 mo ago | Series B | 24 | 2016 | — | 60 patents Breast cancer diagnostic imaging devices (ultrasound/NIR) and body composition analysis tools. | — |
| 38 | Portrai Provider of spatial transcriptomics and AI to accelerate drug discovery and biomarker identification 22Patents top 37%Funding top 38%Innovation top 41%Global bottom 35% All 5 signals ▾Patentstop 37% Fundingtop 38% Innovationtop 41% Globalbottom 35% Marketbottom 22% Patents: 29 patents matched (strict assignee match) · 29 filings since 2022 vs 0 in 2017-21 Funding: Raised $9.9M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 22/100 | $10M | 6 mo ago | Series B | 7 | 2021 | — | 29 patents Patents concentrated in computing, sensing & instrumentation | — |
| 39 | SURGINEX Provider of AI-based drug discovery platform 24AI top 35%Moat top 38%Patents top 39%Innovation top 48% All 9 signals ▾AItop 35% Moattop 38% Patentstop 39% Innovationtop 48% Fundingtop 48% Techbottom 47% Talentbottom 45% Globalbottom 36% Marketbottom 13% AI: Product described with: ai-based, artificial intelligence Moat: Editorial + unicorn rating 4/10 · IP moat: 19 patents rank vs industry peers · Fliar Intelligence Index 24/100 | $9M | 26 mo ago | Series A | 6 | 2020 | Wix eCommerceWixSentry+12 | 19 patents Nanoparticle lipid carriers and hydrogel systems for biliary drug delivery and AI epitope design | — |
| 40 | AIGEN Sciences AI-based drug discovery and designing tool for researchers 35AI top 30%Moat top 38%Funding top 42%Patents top 46% All 8 signals ▾AItop 30% Moattop 38% Fundingtop 42% Patentstop 46% Innovationtop 48% Talentbottom 49% Globalbottom 31% Marketbottom 25% AI: Classified as an AI company · Product described with: ai-based Moat: Editorial + unicorn rating 4/10 · IP moat: 7 patents rank vs industry peers · Fliar Intelligence Index 35/100 | $9M | 11 mo ago | Series A | 8 | 2021 | — | 7 patents Patents concentrated in chemistry & materials | — |
| 41 | Cenyx Biotech Developer of nanozyme based therapeutics for subarachnoid hemorrhage 29Moat top 32%Funding top 37%Patents top 43%Innovation top 46% All 8 signals ▾Moattop 32% Fundingtop 37% Patentstop 43% Innovationtop 46% Talentbottom 45% Marketbottom 34% Globalbottom 31% Techbottom 23% Moat: Editorial + unicorn rating 5/10 · IP moat: 28 patents Funding: Raised $8.2M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 29/100 | $8M | 2 mo ago | Series B | 33 | 2017 | PHPNginxGSAP+7 | 28 patents Antioxidant cerium oxide nanocomposites for therapeutic and anti‑inflammatory biomedical applications | — |
| 42 | Microt Developer of medical devices for glaucoma treatment 45Moat top 32%Innovation top 34%Patents top 36%Funding top 40% All 7 signals ▾Moattop 32% Innovationtop 34% Patentstop 36% Fundingtop 40% Talentbottom 49% Marketbottom 41% Globalbottom 36% Moat: Editorial + unicorn rating 4/10 · IP moat: 35 patents Innovation: 35 patents (top 56% of patent-holders) · 30 filings since 2022 vs 5 in 2017-21 rank vs industry peers · Fliar Intelligence Index 45/100 | $8M | 10 mo ago | Series B | 25 | 2019 | — | 35 patents Ophthalmic implant devices and delivery systems for intraocular pressure regulation | — |
| 43 | S&E bio Developer of cell therapies for neurological disorders | $7M | 41 mo ago | Series A | — | 2019 | — | 647 patents Biomedical polymers and devices for tissue regeneration, wound care, and orthopedic fixation | — |
| 44 | Bionsight Provider of AI-based data analysis software for drug development | $4M | 34 mo ago | Series A | 11 | 2019 | — | 7 patents Patents concentrated in computing, sensing & instrumentation | — |
| 45 | Wellysis Provider of smart wearable wristband and app for ECG monitoring | $4M | 48 mo ago | Series A | 30 | 2019 | — | 18 patents Wearable biosignal sensors and AI-based atrial fibrillation detection for health monitoring | 1 award |
| 46 | EPD Biotherapeutics Developer of targeted protein-degrading therapeutics for cancer and neurological disorders | $3M | 47 mo ago | Seed | 2 | 2021 | — | — | — |
| 47 | Vaxdigm Developer of vaccines and immunotherapies for infectious disease 14Moat top 38%Patents top 45%Innovation top 50%Funding bottom 41% All 6 signals ▾Moattop 38% Patentstop 45% Innovationtop 50% Fundingbottom 41% Globalbottom 31% Marketbottom 26% Moat: Editorial + unicorn rating 4/10 · IP moat: 13 patents Patents: 13 patents matched (strict assignee match) · 13 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 14/100 | $2M | 19 mo ago | Series A | 9 | 2021 | — | 13 patents Viral capsid nanoplatforms for recombinant protein expression and self‑assembling nanoparticle vaccines | — |
| 48 | GlucoFit AI-powered blood sugar management solution | $901K | 27 mo ago | Seed | — | 2022 | TypeScriptGraphQLNode.js+17 | — | — |
| 49 | Sonolux Healthtech Provider of an air based virus detection system 29Talent bottom 45%Funding bottom 44%Global bottom 33% All 3 signals ▾Talentbottom 45% Fundingbottom 44% Globalbottom 33% Talent: 1 named leader on record Funding: Raised $358k across 1 rounds · 1 rounds over 2 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 29/100 | $358K | 18 mo ago | Seed | — | 2022 | — | — | 1 partnership |
| 50 | Karis Bio Developer of cell therapies for cardiovascular diseases 29Funding top 49%Talent bottom 45%Market bottom 38%Global bottom 36% All 4 signals ▾Fundingtop 49% Talentbottom 45% Marketbottom 38% Globalbottom 36% Funding: Raised $307k across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 1 named leader on record rank vs industry peers · Fliar Intelligence Index 29/100 | $307K | 9 mo ago | Funding Raised | 24 | 2020 | — | — | — |
Top 12 Life Sciences companies in Seoul
#1
Public · Seoul, Seoul · founded 2016 · 75 employees$25.7Mraised▾
Public · Seoul, Seoul · founded 2016 · 75 employees
Provider of AI-driven clinical diagnostic testing platform for rare genetics disease. It uses a combination of next-generation sequencing, and advanced machine learning and deep learning algorithms to analyze whole patient genomes for disease-causing mutations. The company is developing a single test that can detect more than 4000 rare genetic disorders.
Fliar Intelligence Index™ 74how this company ranks against its industry peers
Product
top 19%Tech
top 22%AI
top 25%Patents
top 26%Talent
top 28%Innovation
top 32%Product: 3 distinct product lines · Company stage: Public
Tech: 49 technologies across 5/8 capability areas · Cloud: Amazon Cloudfront, Amazon S3 · Observability: Datadog, Sentry
AI: Product described with: ai-driven, deep learning, machine learning
Audience (LinkedIn): 3k LinkedIn followers — 14.2% of this cohort's audience
Activity (LinkedIn): 1 partnerships (incl. MASS Diagnostics ( Genetics - Egypt)) announced in 12 mo
Funding rounds
- Apr 2026Series D$20.3M
- Mar 2021Series C$13M
- Oct 2019Series B$10M
- Jul 2018Series A$2.7M
Investors
Korea Development Bank Europe, The Wells Investment, JW Asset Management, Yuanda Financial Holdings, Shinhan Financial Group, AVentures Capital
Tech stack
Amazon CloudfrontAmazon S3Amazon Web ServicesApache Http ServerApple Icloud MailCart Functionality
#2
Public · Seoul, Seoul · founded 2008 · 48 employees$23.2Mraised▾
Public · Seoul, Seoul · founded 2008 · 48 employees
Shaperon is the developer of therapies for multiple diseases. The platform is mainly focusing on inflammatory diseases, dermatitis, nonotherapy for cancer and developing multi-targeting stable protein structure. The platform also has multiple pipeline products include Nugel for atopic dermatitis indication are in phase two clinical trials, Nusepin for sepsis indication is in phase one clinical trials, and NuCerin for Alzheimer's indication is in preclinical stage among others.
Fliar Intelligence Index™ 24how this company ranks against its industry peers
Patents
top 20%Innovation
top 24%Funding
top 29%Moat
top 35%News
top 39%Talent
bottom 49%Patents: 116 patents matched (strict assignee match) · 105 filings since 2022 vs 9 in 2017-21 · Latest publication 2026
Innovation: 116 patents (top 24% of patent-holders) · 105 filings since 2022 vs 9 in 2017-21
Funding: Raised $23.2M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) · Last round Post IPO (Apr 2026)
Funding rounds
- Apr 2026Post IPO$5.8M
- Nov 2025Post IPO$17.4M
Founders & team
Investors
Mirae Asset, Daishin Securities, Samsung Securities, Korea Investment Holdings, KB Securities, JX Partners
#3
Public · Seoul, Seoul · founded 2012 · 65 employees$30Mraised▾
Public · Seoul, Seoul · founded 2012 · 65 employees
ROKIT HEALTHCARE provides 4D bio-printer solutions for tissue regenerative. The company offers its propriety technology for organ regeneration and 3D bio-fabrication technologies for personalized therapy in the areas of skin, cartilage, retina and heart patch regeneration. The company flagship product INVIVO, is a sterilized printer equipped for developing the biomolecules, and polymers to create 3D structures.
Fliar Intelligence Index™ 64how this company ranks against its industry peers
Patents
top 24%Innovation
top 26%Tech
top 28%Product
top 28%Moat
top 29%Funding
top 33%Patents: 168 patents matched (strict assignee match) · 84 filings since 2022 vs 84 in 2017-21 · Latest publication 2026
Innovation: 168 patents (top 10% of patent-holders) · 84 filings since 2022 vs 84 in 2017-21 · Deep-tech classification: Tech Hardware
Tech: 40 technologies across 5/8 capability areas · Cloud: Cloudflare, Google Cloud · Devops: Nginx
Audience (LinkedIn): 3k LinkedIn followers — 12.6% of this cohort's audience
Activity (LinkedIn): 3 partnerships (incl. Northwell Health System) announced in 12 mo
Funding rounds
- Mar 2026Post IPO$42.1M
- Jul 2020Series C—
- Jan 2019Series B$9.9M
- 2015Grant (prize money)$3M
Founders & team
Investors
Daily Partners, Korean Development Bank, KB Investment, DRADS Capital, Weiss Asset Management, Oasis
Tech stack
Google AnalyticsGoogle CloudGoogle Cloud CdnGoogle WorkspaceHstsHttp/3
#4
Series B · Seoul, Seoul · founded 2020 · 23 employees$47Mraised▾
Series B · Seoul, Seoul · founded 2020 · 23 employees
Provider of a drug discovery platform that integrates AI, physics, and chemistry to design various biomolecules. The technology enables the prediction of solubility, binding affinity, and other properties of these molecules, which is crucial in the drug discovery process. The platform helps in molecular design, protien structure prediction, protien interaction and prediction for drug development.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Funding
top 28%News
top 36%Talent
bottom 49%Market
bottom 44%Global
bottom 33%Funding: Raised $47.0M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) · Last round Series B (Feb 2026)
News: 3 BI events in 12 mo (of 3 tracked, 1 types) · Top themes: Funding
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Funding rounds
- Feb 2026Series B$29M
- 2022Series A$18M
Founders & team
Investors
InterVest, Daily Partners, Yuanta Investment, Korean Development Bank, SL Investment, Ncore Ventures
#5
Series C · Seoul, Seoul · founded 2021 · 18 employees$23.5Mraised▾
Series C · Seoul, Seoul · founded 2021 · 18 employees
Developer of immunotherapeutics for cancer treatment. It offers multi-specific antibodies which include MB101, MB201, MB301, and MB401 for the treatment of multiple cancer. It offers multi-antibody platform technology to develop multiple antibodies.
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Funding
top 29%Talent
bottom 49%Market
bottom 36%Global
bottom 29%Funding: Raised $23.5M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series C (Mar 2026)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Market: 18 employees
Funding rounds
- Mar 2026Series C$23.5M
- Series A—
- Series B—
Founders & team
Investors
Premier Partners, Partners Investment, Korean Development Bank, Wonik Investment Partners, Shinhan Financial Group, Atinum Investment
#6
Series B · Seoul, Seoul · founded 2017 · 33 employees$8.2Mraised▾
Series B · Seoul, Seoul · founded 2017 · 33 employees
Developer of nanozyme based therapeutics for subarachnoid hemorrhage. The candidate CX213 is a nano-biotech agent that removes superoxide, hydrogen peroxide, and hydroxyl radicals. It is used for the treatment of acute inflammatory injuries and subarachnoid hemorrhage.
Fliar Intelligence Index™ 29how this company ranks against its industry peers
Moat
top 32%Funding
top 37%Patents
top 43%Innovation
top 46%Talent
bottom 45%Market
bottom 34%Moat: Editorial + unicorn rating 5/10 · IP moat: 28 patents
Funding: Raised $8.2M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series B (Mar 2026)
Patents: 28 patents matched (strict assignee match) · 18 filings since 2022 vs 10 in 2017-21 · Latest publication 2026
Funding rounds
- Mar 2026Series B$8.2M
Founders & team
Investors
SL Investment, Scale Up Partners, SBI Investment Korea, Partners Investment, InterValue Partners, CKD Venture Capital
#7
Series B · Seoul, Seoul · founded 2021 · 26 employees$57.4Mraised▾
Series B · Seoul, Seoul · founded 2021 · 26 employees
Developer of antibody-based drugs to treat neurological conditions. The company is developing a chimeric fusion protein platform to address the concerns of antibody-induced neuroinflammation and subsequent ARIA (Amyloid-Related Imaging Abnormalities) often observed from existing antibody drugs that utilize FcR-mediated phagocytosis of microglia, by utilizing TAM receptor.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Funding
top 28%Moat
top 31%Patents
top 38%Innovation
top 45%Talent
bottom 49%Global
bottom 40%Funding: Raised $57.4M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) · Last round Series B (Jul 2025)
Moat: Editorial + unicorn rating 4/10 · IP moat: 24 patents · Soonicorn
Patents: 24 patents matched (strict assignee match) · 24 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Audience (LinkedIn): 592 LinkedIn followers — 2.7% of this cohort's audience
Funding rounds
- Jul 2025Series B$42M
- Apr 2023Series A$15.4M
- 2022Seed—
Founders & team
Investors
DSC Investment, WOORI Venture Partners, Korean Development Bank, Aju IB Investment, QUAD, Company K Partners
#8
Series B · Seoul, Seoul · founded 2021 · 7 employees$9.9Mraised▾
Series B · Seoul, Seoul · founded 2021 · 7 employees
Provider of spatial transcriptomics and AI to accelerate drug discovery and biomarker identification. The platform allow researchers to analyse the pathophysiology of diseases and discovers biomarkers, identify targets for new drugs, analyse the mode of action of drugs, and discover biomarkers.
Fliar Intelligence Index™ 22how this company ranks against its industry peers
Patents
top 37%Funding
top 38%Innovation
top 41%Global
bottom 35%Market
bottom 22%Patents: 29 patents matched (strict assignee match) · 29 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Funding: Raised $9.9M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series B (Dec 2025)
Innovation: 29 patents (top 60% of patent-holders) · 29 filings since 2022 vs 0 in 2017-21
Audience (LinkedIn): 639 LinkedIn followers — 2.9% of this cohort's audience
Funding rounds
- Dec 2025Series B$9.9M
Investors
STIC Ventures, BNH INVESTMENT, Kakao Ventures, Envisioning Partners, BonAngels Venture Partners, Pearl Abyss Capital
#9
Series C · Seoul, Seoul · founded 2018 · 30 employees$18.8Mraised▾
Series C · Seoul, Seoul · founded 2018 · 30 employees
Developing gene therapies using adeno associated virus technology to treat various diseases. It is focused on treating genetic disorders and has developed several pipeline products, including NG101, which is currently in a Phase 1/2a clinical trial for the treatment of patients with a rare genetic disorder. It is also engaged in developing additional gene therapy candidates targeting various neurodegenerative disorders and rare diseases.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Funding
top 33%Market
top 50%Talent
bottom 49%Global
bottom 36%Funding: Raised $18.8M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series C (Sep 2025)
Market: 30 employees (top 50% of Life Sciences)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 259 LinkedIn followers
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Sep 2025Series C$18.8M
Founders & team
Investors
Premier Partners, Yuanta Investment, Ulmer Investments
#10
Series B · Seoul, Seoul · founded 2016 · 29 employees$14.3Mraised▾
Series B · Seoul, Seoul · founded 2016 · 29 employees
Developer of small molecule therapeutics for infectious diseases. The company is developing a treatment through bacteriophage for multi-drug resistant bacterias which include Pseudomonas, E.oli, Acinetobacter, and others.
Fliar Intelligence Index™ 32how this company ranks against its industry peers
Funding
top 39%Talent
bottom 49%Market
bottom 44%Global
bottom 29%Funding: Raised $14.3M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) · Last round Series B (Sep 2025)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Market: 29 employees
Funding rounds
- Sep 2025Series B$14.3M
- Oct 2024Series B—
Founders & team
Investors
Schmidt, DSC Investment
#11
Series B · Seoul, Seoul · founded 2019 · 25 employees$7.9Mraised▾
Series B · Seoul, Seoul · founded 2019 · 25 employees
Developer of medical devices for glaucoma treatment. The company's products include Astream a micro-sized glaucoma implant device and Blecure MD Gel a wound healing dressing gel to protect damaged skin.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Moat
top 32%Innovation
top 34%Patents
top 36%Funding
top 40%Talent
bottom 49%Market
bottom 41%Moat: Editorial + unicorn rating 4/10 · IP moat: 35 patents
Innovation: 35 patents (top 56% of patent-holders) · 30 filings since 2022 vs 5 in 2017-21 · Deep-tech classification: Tech Hardware
Patents: 35 patents matched (strict assignee match) · 30 filings since 2022 vs 5 in 2017-21 · Latest publication 2026
Funding rounds
- Jul 2025Series B$7.9M
Founders & team
Investors
Kiwoom Investment, SL Investment, Horizon Investments, IBK Capital, Samsung Catalyst Fund
#12
Series A · Seoul, Seoul · founded 2021 · 8 employees$8.8Mraised▾
Series A · Seoul, Seoul · founded 2021 · 8 employees
AI-based drug discovery and designing tool for researchers. The company has developed a proprietary tool AIGEN Discovery that assists with the discovery and designing of new drugs. The system can be used for drug targeting, data analysis, novel compounds optimization, and more.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
AI
top 30%Moat
top 38%Funding
top 42%Patents
top 46%Innovation
top 48%Talent
bottom 49%AI: Classified as an AI company · Product described with: ai-based
Moat: Editorial + unicorn rating 4/10 · IP moat: 7 patents
Funding: Raised $8.8M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) · Last round Series A (Jul 2025)
Funding rounds
- Jul 2025Series A—
- Oct 2024Series A$8.8M
Founders & team
Investors
Premier Partners, K2 Investment Partners, Medytox Venture, Partners Investment, QUAD, Scale Up Partners
Funding & investor landscape
$3.5Btotal disclosed funding
71companies funded
104disclosed rounds
3rounds last 90 days
Most active investors
Notable founders
Seung Seong
Founder & CEO · Shaperon
Seokhwan You
Chairman & Ceo · ROKIT Healthcare
Chaok Seok
CEO · Galaxy
Kim Seop
CEO · Must Bio
Seung-Hoon Lee
CEO · Cenyx Biotech
Sanghoon Park
Co-Founder & Ceo · Illimis Therapeutics
Kim Jong-muk
CEO · NeuracleGenetics
Yong Dong- eun
CEO · Microbiotics
Jongcheol Han
CEO · Microt
Jaewoo Kang
CEO · AIGEN Sciences
Yongtae Kim
Co-Founder & CEO · Mepsgen
Servo Optical
CEO · Uvic Steratics
Prism market signals · South Korea · country-scoped Prism corpus, 618,093 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH IN SEOUL · Health & Bio
How research on Biotechnology in Seoul is moving
A read on the academic research around Biotechnology in Seoul — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 68 papers.
Seoul National University leads research on CRISPR, cancer nanotheranostics, and stem cells, with recent output heavily optimistic, reflecting confident advancement in biotechnology innovation.
68 papers · stance +0.47 · 27% breakthrough · 14% concern
top institutions
- Seoul National University53
- Seoul National University Hospital5
- Seoul National University of Science and Technology4
- University of Seoul2
- Seoul Women\'s University2
leading researchers
Hokyoung Son · Kim, V. Narry · Rui Liu · Seo, Jenny · Soobin Shin · A.A. АDAMBAYEVA
prism intelligence · tone & topics
87% positive · 9% critical tone
HealthMedical ResearchPharmaceuticalsAgricultureBiologyGenetics
▲
Breakthroughs16 · 24%
▼ 50%→22% share
▼0.4× share momentum0 median citations81% since 2021mostly empirical
In vivo, Histone, and Antibody research rising but Breakthroughs field-share halved from 50% to 22%.
rising sub-themes (early→recent)
- In vivo2
- Histone2
- Antibody2
- Strain (injury)2
- Mesoporous silica1
Landmark Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins · 1,853 cites
◆
Advancements35 · 51%
50%→50% share
▲1.0× share momentum0 median citations83% since 2021mostly empirical
Mesenchymal stem cell and DNA damage papers tripled, sustaining Advancements at steady 50% field-share.
rising sub-themes (early→recent)
- Mesenchymal stem cell1→3
- DNA damage1→3
Landmark Safety of Intravenous Infusion of Human Adipose Tissue-Derived Mesenchymal Stem Cells in Animals and Humans · 590 cites
▼
Concerns8 · 12%
▲ 0%→12% share
0 median citations88% since 2021mostly reviews
Genotoxicity concerns newly emerging — Micronucleus test and Comet assay signals pushed share from 0% to 12%.
rising sub-themes (early→recent)
- Genotoxicity1
- Micronucleus test1
- Comet assay1
- Micronucleus1
- DNA damage1
Landmark Nano‐Sized CT Contrast Agents · 635 cites
Common questions
How many Life Sciences companies are there in Seoul, South Korea?
Radar tracks 405 indexable Life Sciences companies headquartered in Seoul, South Korea that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in Seoul, South Korea?
The Life Sciences companies in Seoul, South Korea on this list have raised a combined $3.5B in disclosed equity funding across 71 funded companies.
Which is the highest-funded Life Sciences company in Seoul, South Korea?
Cellid is the highest-funded Life Sciences company in Seoul, South Korea, with $2.4B in disclosed equity funding.
How many Life Sciences companies in Seoul, South Korea are funded?
71 of the 405 Life Sciences companies in Seoul, South Korea on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in Seoul, South Korea?
None of the Life Sciences companies in Seoul, South Korea on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in Seoul, South Korea Life Sciences companies?
The most active investors in Seoul, South Korea Life Sciences companies on this list include Korea Investment Holdings, DSC Investment, IMM Investment, Company K Partners, Daily Partners.
Rohit KhannaTrends & Stories
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.